TraffikGene-Tx · TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery

TraffikGene-Tx: Targeted and Dynamic RNA Peptide Vehicles-Unmet Clinical Need and ProblemRare and complex genetic diseases lead to significant disability, death and associated cost burdens for society. Complex genetic diseases include cardiovascular diseases (CVD) and cancer, the two leading causes of death in the EU and up to 36 million Europeans suffer from rare genetic diseases. Nucleic acid therapeutics (NATs) represent a potential treatment, but they are hampered by the delivery problem. Systemically administered naked RNA is quickly degraded by endonucleases, can provoke adverse immune reactions and has off-target toxicity. Viral and lipid nanoparticle (LNP) delivery vectors have toxic side-effects and are difficult to produce and target.-The SolutionTraffikGenes RNA delivery platform is:Safe: biodegradable, non-immunogenic peptide carriers that cleave to avoid the detergent toxicity of LNPs.Targetable: beyond the liver, to the spleen, lungs and heart with excellent delivery to the cytosol.Scalable: Production is automated, simple and cheap.TraffikGene combines modular design with high-throughput screening which will feed into AI-enhanced SAR-based predictive vehicle design. This will accelerate and de-risk NAT drug development.-The ProjectTraffikGene will capitalize on the current breakthroughs in healthcare represented by NATs. RNA therapeutics (mRNA, saRNA, siRNA, lncRNA, miRNA) are now emerging driven by the success of mRNA vaccines and TraffikGene will deliver them to the tissues where they are needed. We aim to break new ground in the field of RNA, validate our delivery vehicles and start developing our pipeline to advance to the preclinical trial stage with therapeutic RNAs. We aim to launch our company of customised peptide carriers for any RNA medicine with a proprietary flagship RNA-based immunotherapy. Our products will bring many promising NATs to the market, and help millions of patients, while reducing health care costs.